Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Primary Myelofibrosis 1Polycythemia Vera 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1

Interventions

Rituximab 45Cyclophosphamide 32Lenalidomide 24fludarabine 20zanubrutinib 13venetoclax 12obinutuzumab 12orelabrutinib 11fludarabine phosphate 10Bendamustine Hydrochloride 10Magnetic Resonance Spectroscopy 9Whole-Body Irradiation 8Prednisone 8pirtobrutinib 7ibrutinib 7Vincristine 7Specimen Handling 7CT-P10 7Mycophenolic Acid 6Biopsy 6Doxorubicin 5tafasitamab 4pembrolizumab 3acalabrutinib 3Tacrolimus 3Sirolimus 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Nivolumab 3Melphalan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × umbralisib × 1 year × Clear all
NCT03919175 2026-02-27

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Massachusetts General Hospital

Phase 2 Terminated
18 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡